SCHEMBL4440205

SCHEMBL4440205

c1ccc(Oc2ncnc(Oc3ccccc3)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
LTA4H P09960 2/20 0.50
PAX8 Q06710 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.46
CYP1A2 P05177 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2C9 P11712 1/20 0.46
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
GAA P10253 1/20 0.44
ALDH1A1 P00352 4/20 0.44
HTT P42858 1/20 0.44
GLA P06280 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
MAP4K4 O95819 1/20 0.43
TRPA1 O75762 1/20 0.42
POLB P06746 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3416586 0.86 MAP4K4 (0.45) TSHRLTA4HPAX8SMN1; SMN2CYP1A2
SCHEMBL10341611 0.86 KMT2A (0.46) TSHRLTA4HPAX8SMN1; SMN2CYP1A2
SCHEMBL1006428 0.85 PAX8 (0.63) TSHRLTA4HPAX8SMN1; SMN2NPC1
SCHEMBL20298287 0.84 MEN1 (0.46) TSHRLTA4HPAX8SMN1; SMN2CYP1A2
SCHEMBL24262518 0.82 KMT2A (0.61) TSHRLTA4HPAX8SMN1; SMN2KMT2A
SCHEMBL28985646 0.81 PAX8 (0.40) TSHRLTA4HPAX8SMN1; SMN2CYP1A2
SCHEMBL108195 0.81 LTA4H (0.50) TSHRLTA4HPAX8SMN1; SMN2CYP1A2
SCHEMBL11810231 0.80 ALDH1A1 (0.41) TSHRLTA4HPAX8SMN1; SMN2CYP1A2
SCHEMBL15952111 0.80 BCL6 (0.56) CYP1A2NPC1RAB9ACYP2C19CYP2C9
SCHEMBL28468081 0.78 PIN1 (0.44) TSHRPAX8SMN1; SMN2CYP1A2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114901665-B Use of triazolotriazine derivatives in the treatment of diseases 浙江春禾医药科技有限公司 2025-02-18 CN disclosed
CN-111051309-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-26 CN disclosed
CN-111164084-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-23 CN disclosed
US-20230048888-A1 USE OF TRIAZOLOTRIAZINE DERIVATIVE IN TREATMENT OF DISEASES ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-02-16 US disclosed
EP-4083044-A1 USE OF TRIAZOLOTRIAZINE DERIVATIVE IN TREATMENT OF DISEASES Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) 2022-11-02 EP disclosed
CN-114901665-A Use of triazolotriazine derivatives for the treatment of diseases 浙江春禾医药科技有限公司 2022-08-12 CN disclosed
US-8865620-B2 Heat-sensitive coating compositions based on resorcinyl triazine derivatives DATALASE, LTD. (GB) 2014-10-21 US disclosed
US-20110311786-A1 HEAT-SENSITIVE COATING COMPOSITIONS BASED ON RESORCINYL TRIAZINE DERIVATIVES DATALASE LTD 2011-12-22 US disclosed
EP-2121853-A1 HEAT-SENSITIVE COATING COMPOSITIONS BASED ON RESORCINYL TRIAZINE DERIVATIVES BASF SE (DE) 2009-11-25 EP disclosed
WO-2008110487-A1 HEAT-SENSITIVE COATING COMPOSITIONS BASED ON RESORCINYL TRIAZINE DERIVATIVES BASF SE (CH) 2008-09-18 WO disclosed
US-3966680-A Phenoxy-s-triazine chain coupler for polyesterification and novel polyesters MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311786-A1 HEAT-SENSITIVE COATING COMPOSITIONS BASED ON RESORCINYL TRIAZINE DERIVATIVES OR10J3, NR3C2, NR1H2 TSHR 299/4885LTA4H 2605/4885PAX8 1375/4885
US-20230048888-A1 USE OF TRIAZOLOTRIAZINE DERIVATIVE IN TREATMENT OF DISEASES TPMT, TPP2, TMPRSS15 TSHR 805/4885LTA4H 511/4885PAX8 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.